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Abstract
Purpose Low blood 25-hydroxyvitamin D (25(OH)D) concentration has been proposed as a potential causal factor in 
COVID-19 risk. We aimed to establish whether baseline serum 25(OH)D concentration was associated with COVID-19 
mortality, and inpatient confirmed COVID-19 infection, in UK Biobank participants.
Methods UK Biobank recruited 502,624 participants aged 37–73 years between 2006 and 2010. Baseline exposure data, 
including serum 25(OH)D concentration, were linked to COVID-19 mortality. Univariable and multivariable Cox propor-
tional hazards regression analyses were performed for the association between 25(OH)D and COVID-19 death, and Poisson 
regression analyses for the association between 25(OH)D and severe COVID-19 infection.
Results Complete data were available for 341,484 UK Biobank participants, of which 656 had inpatient confirmed COVID-19 
infection and 203 died of COVID-19 infection. 25(OH)D concentration was associated with severe COVID-19 infection and 
mortality univariably (mortality per 10 nmol/L 25(OH)D HR  0.92; 95% CI 0.86–0.98; p = 0.016), but not after adjustment 
for confounders (mortality per 10 nmol/L 25(OH)D HR 0.98; 95% CI = 0.91–1.06; p = 0.696). Vitamin D insufficiency or 
deficiency was also not independently associated with either COVID-19 infection or linked mortality.
Conclusions Our findings do not support a potential link between 25(OH)D concentrations and risk of severe COVID-19 
infection and mortality. Randomised trials are needed to prove a beneficial role for vitamin D in the prevention of severe 
COVID-19 reactions or death.
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In the hunt for modifiable COVID-19 risk factors, vitamin 
D has gained a lot of attention both in the media and within 
the scientific community [1]. Proponents of such a link cite 
a few early studies that present circumstantial evidence. 
They are either ecological, at an individual level but una-
ble to fully adjust for potential confounders, or they meas-
ured 25-hydroxyvitamin D (25(OH)D) concentration once 
patients were already hospitalised with COVID-19 which 
introduces reverse causation, as vitamin D is a negative 
acute phase reactant [2].
Despite the sparse evidence on vitamin D in COVID-19 
[3], the UK government led an urgent review into whether 
there is any link. It concluded that “There is no evidence to 
support taking vitamin D supplements to specifically prevent 
or treat COVID-19” [4]. By contrast, the Welsh COVID-19 
risk assessment tool includes vitamin D supplementation 
as part of its recommendations [5]. Furthermore, a recent 
review conducted by the Scientific Advisory Committee on 
Nutrition found insufficient evidence to support recommend-
ing vitamin D supplementation to prevent acute respiratory 
tract infections in the general UK population [6].
We previously observed no evidence of an association 
between baseline serum 25(OH)D concentration and testing 
positive for SARS-CoV-2 in hospital in UK Biobank once 
potential confounders were adjusted for [7]. Importantly, 
some of the variables that were associated with increased 
COVID-19 risk in our sample, for example lower socioeco-
nomic status, being Black or South Asian, or being over-
weight or obese, are also associated with lower vitamin D. 
This suggests that the positive findings of other studies may 
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in part be due to inadequate adjustment. Another recent 
study of UK Biobank data replicated this finding [8], but it 
would be more informative to relate 25(OH)D concentration 
to COVID-19-related mortality.
Table 1  Univariable association 
between baseline covariates and 
confirmed COVID-19 mortality, 
and confirmed inpatient 
COVID-19 infection
HR hazard ratio, CI confidence interval, IRR incidence rate ratio
COVID-19 mortality Inpatient COVID-19 infection
HR (95% CI) p IRR (95% CI) p
Sex
 Female 1 1
 Male 2.49 (1.85–3.35)  < 0.001 1.50 (1.29–1.75)  < 0.001
Self-reported ethnicity
 White 1 1
 Black 7.44 (4.30–12.9)  < 0.001 3.14 (2.17–4.53)  < 0.001
 South Asian 1.76 (0.65–4.74) 0.264 2.69 (1.87–3.89)  < 0.001
Townsend deprivation quintile
 1 1 1
 2 1.05 (0.64–1.72) 0.855 1.04 (0.79–1.36) 0.802
 3 0.95 (0.57–1.58) 0.845 1.08 (0.82–1.42) 0.584
 4 1.47 (0.93–2.34) 0.101 1.37 (1.06–1.77) 0.016
 5 2.56 (1.67–3.91)  < 0.001 2.23 (1.75–2.83)  < 0.001
Household income
 < £18,000 1 1
 £18 k-£30,999 0.47 (0.33–0.67)  < 0.001 0.62 (0.51–0.76)  < 0.001
 £31 k-£51,999 0.42 (0.29–0.60)  < 0.001 0.55 (0.45–0.68)  < 0.001
 £52 k-£100,000 0.28 (0.18–0.44)  < 0.001 0.44 (0.34–0.55)  < 0.001
 > £100,000 0.14 (0.04–0.43) 0.001 0.36 (0.23–0.56)  < 0.001
Overall health rating
 Excellent 1 1
 Good 1.52 (0.94–2.43) 0.085 1.49 (1.15–1.93) 0.003
 Fair 3.49 (2.14–5.68)  < 0.001 2.46 (1.86–3.26)  < 0.001
 Poor 4.86 (2.59–9.12)  < 0.001 4.97 (3.54–6.96)  < 0.001
Long-standing illness, disability or infirmity
 No 1 1
 Yes 2.80 (2.13–3.70)  < 0.001 1.84 (1.58–2.15)  < 0.001
Smoking status
 No 1 1
 Yes 1.36 (0.91–2.02) 0.134 1.34 (1.07–1.69) 0.013
BMI category
 Normal weight 1 1
 Underweight 1.86 (0.26–13.6) 0.539 1.38 (0.44–4.31) 0.584
 Overweight 1.82 (1.23–2.67) 0.002 1.50 (1.23–1.83)  < 0.001
 Obese 3.13 (2.12–4.62)  < 0.001 2.02 (1.64–2.49)  < 0.001
Diabetes
 No 1 1
 Yes 5.06 (3.59–7.13)  < 0.001 2.49 (1.96–3.17)  < 0.001
Current age (years) 1.13 (1.11–1.16)  < 0.001 1.01 (1.00–1.02) 0.007
 Baseline systolic blood 
pressure (mmHg)
1.02 (1.02–1.03)  < 0.001 1.00 (0.999–1.01) 0.123
 Baseline diastolic 
blood pressure 
(mmHg)
1.01 (0.998–1.03) 0.099 1.01 (0.999–1.01) 0.109
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In the current analysis, we therefore linked baseline 
serum 25(OH)D concentration in 341,484 UK Biobank par-
ticipants with complete data on covariates to Death Register 
data. In the sample, 203 participants died due to COVID-19 
infection. Deaths occurred between the 5th of March and 
25th of April 2020. We explored whether serum 25(OH)D 
concentration as a continuous measurement, or vitamin D 
deficiency or insufficiency (defined as serum 25(OH)D < 25 
and < 50 nmol/L, respectively), were associated with risk of 
COVID-19 death using Cox proportional hazards regression 
analysis.
Univariably, several covariates were associated with 
COVID-19 mortality and infection (Table  1). Notably, 
black and South Asian ethnicity, obesity, and lower socio-
economic status are also associated with lower 25(OH)D 
concentration.
The COVID-19 mortality results followed the same pat-
tern that we previously observed for COVID-19 infection 
[7]. Lower 25(OH)D concentration and vitamin D defi-
ciency were both associated with higher risk of COVID-
19 death univariably, but not after adjustment for potential 
confounders (Table 2). Multivariate models were adjusted 
for all measured confounders as detailed in the table leg-
end. Vitamin D insufficiency was not associated with risk 
of COVID-19 death univariably or multivariably. Further-
more, we repeated our previous analysis of the association 
between 25(OH)D and confirmed COVID-19 infection with 
additional cases, using univariable and multivariable pois-
son regression of inpatient diagnosed infection. There were 
656 confirmed inpatient COVID-19 cases. Again, 25(OH)
D concentration and vitamin D deficiency were associated 
with COVID-19 infection univariably but not multivariably 
(Table 2).
The variables significantly associated with risk of 
COVID-19 mortality in multivariate analysis were age 
(HR 1.12; 95% CI 1.10–1.15; p < 0.001 per year), male sex 
(HR 2.12; 95% CI 1.56–2.89; p < 0.001), black ethnicity 
(HR 8.13; 95% CI 4.56–14.50; p < 0.001), obesity (HR 1.68; 
95% CI 1.11–2.56; p = 0.015 compared with normal weight), 
socioeconomic deprivation (highest Townsend deprivation 
quintile compared with lowest HR 1.96; 95% CI 1.24–3.09; 
p = 0.004), and diabetes (HR 1.96; 95% CI 1.34–2.86; 
p = 0.001). These findings are consistent with other studies, 
lending strong external validity.
The main limitation of using UK Biobank for this analy-
sis is the ~ 10 year time period between baseline 25(OH)D 
measurement and COVID-19 infection. We examined the 
concordance rates of vitamin D deficiency in a subsample 
of 15,473 participants who had measurements taken both at 
baseline and at a follow-up visit (on average 4.3 years later). 
Concordance in this group was 84%.
If there is a causal link, vitamin D supplements would 
present an appealingly cheap low risk intervention. How-
ever, currently there is no evidence that supplements will 
reduce risk of COVID-19 infection [4], or acute respira-
tory tract infections more generally [6]. NHS guidelines 
already recommend that all UK residents take vitamin D 
supplements in the winter, and furthermore that certain 
groups who are more likely to be deficient (for example 
those with darker skin) take them throughout the year 
[9]. We await the results of randomised controlled tri-
als to determine whether there should be any change to 
these guidelines and consequently clinical practice. For 
now, recommendations for vitamin D supplementation to 
lessen COVID-19 risks appear premature and, although 
they may cause little harm, they could provide false reas-
surance leading to changes in behaviour that increase risk 
of infections.
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Table 2  Association between baseline serum 25(OH)D and confirmed COVID-19 mortality, and confirmed inpatient COVID-19 infection
Participants who died of COVID-19 had a median age at death of 76 years (interquartile range 71–78 years)
HR hazard ratio, CI confidence interval, IRR incidence rate ratio
*Adjusted for age, sex, ethnicity, month of assessment, Townsend deprivation quintile, household income, BMI category, smoking status, diabe-
tes, systolic blood pressure, diastolic blood pressure, self-reported health rating, and long-standing illness, disability or infirmity
COVID-19 mortality Inpatient COVID-19 infection
Univariable Multivariable* Univariable Multivariable*
HR (95% CI) p value HR (95% CI) p value IRR (95% CI) p value IRR (95% CI) p value
25(OH)D (per 10 nmol/L) 0.92 (0.86–0.98) 0.016 0.98 (0.91–1.06) 0.696 0.93 (0.90–0.97)  < 0.001 1.00 (0.96–1.05) 0.888
Vitamin D deficient (25(OH)
D < 25 nmol/L)
1.61 (1.14–2.27) 0.007 1.21 (0.83–1.76) 0.311 1.56 (1.28–1.90)  < 0.001 1.10 (0.88–1.37) 0.404
Vitamin D insufficient (25(OH)
D < 50 nmol/L)
1.29 (0.97–1.72) 0.076 1.02 (0.75–1.38) 0.919 1.33 (1.14–1.56)  < 0.001 1.06 (0.89–1.26) 0.525
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Code availability All analyses were undertaken using Stata v14.
Availability of data and material Data can be accessed via the proce-
dures detailed in the UK Biobank website (https ://www.ukbio bank.
ac.uk/).
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